Table 2.
Effect of miltefosine alone or combined with benznidazole on parasitemia parameters in BALB/cJ mice infected with Trypanosoma cruzi (VD strain).
| Treatment(mg/kg/day) | n | MPR(trypomastigotes/mL) | MPRreduction (%) | Survival(%) |
|---|---|---|---|---|
| Subtherapeutic regime | ||||
| MLT (25) | 4 | 9.06x104 ( ± 4.13x104)A | 76.23A | 4/4 (100)A |
| BZ (5) | 4 | 7.8x1x104 ( ± 3.13x104)A | 79.51A | 4/4 (100)A |
| MLT (25) + BZ (5) | 4 | 7.81x104 ( ± 4.49x104)A | 79.51A | 4/4 (100)A |
| NT (—) | 4 | 3.81x105 ( ± 1.64x105)B | —– | 2/4 (50)B |
| Additive regime* | ||||
| BZ (100) | 8 | 2.17x104 ( ± 1.30x104)A | 94.31A | 8/8 (100)A |
| MLT (50) + BZ (50) | 8 | 3.63x104 ( ± 1.24x104)A | 90.49A | 8/8 (100)A |
| NT | 12 | 3.81x105 ( ± 1.64x105)B | — | 0/12 (0)B |
NT, infected non-treated. MLT, miltefosine. BZ, benznidazole. MPR, Maximum parasitemia reached.
Female BALB/cJ mice were infected with 500 trypomastigotes of T. cruzi VD strain; treatment started at 8 dpi and was administered orally for 20 consecutive days. * Results obtained from two independent assays.
Different letters indicate significant differences (Kruskal-Wallis; p < 0.05).
Values are expressed as mean (± standard deviation).